Home
About Us
The Repeatome
Our Science
Join Us
News

ROME Therapeutics

LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses | American College of Rheumatology Convergence 2022

Post navigation

Previous PostPrevious Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition

Next PostNext ROME Therapeutics company presentation | 41st J.P. Morgan Healthcare Conference

201 Brookline Ave. Suite 1001, Boston, MA 02215
© 2023 ROME Therapeutics. All rights reserved.

Contact Us
Privacy Policy
Terms of Use